Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Vistin Pharma ASA (VP4.F)

2.1000
+0.1150
+(5.79%)
At close: April 25 at 10:37:41 AM GMT+2
Loading Chart for VP4.F
  • Previous Close 1.9850
  • Open 1.9650
  • Bid 1.9950 x --
  • Ask 2.0500 x --
  • Day's Range 1.9650 - 2.1000
  • 52 Week Range 1.6950 - 2.3900
  • Volume 50
  • Avg. Volume 8
  • Market Cap (intraday) 93.124M
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) 17.50
  • EPS (TTM) 0.1200
  • Earnings Date Apr 25, 2025
  • Forward Dividend & Yield 0.11 (5.08%)
  • Ex-Dividend Date Jun 4, 2025
  • 1y Target Est --

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.

www.vistin.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VP4.F

View More

Performance Overview: VP4.F

Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .

YTD Return

VP4.F
6.06%
OBX Total Return Index (OBX.OL)
4.10%

1-Year Return

VP4.F
84.48%
OBX Total Return Index (OBX.OL)
8.57%

3-Year Return

VP4.F
233.43%
OBX Total Return Index (OBX.OL)
25.01%

5-Year Return

VP4.F
829.74%
OBX Total Return Index (OBX.OL)
105.07%

Compare To: VP4.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VP4.F

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    89.21M

  • Enterprise Value

    87.20M

  • Trailing P/E

    17.64

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.59

  • Price/Book (mrq)

    3.59

  • Enterprise Value/Revenue

    2.42

  • Enterprise Value/EBITDA

    9.15

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.61%

  • Return on Assets (ttm)

    13.53%

  • Return on Equity (ttm)

    19.85%

  • Revenue (ttm)

    429.5M

  • Net Income Avi to Common (ttm)

    62.75M

  • Diluted EPS (ttm)

    0.1200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.79M

  • Total Debt/Equity (mrq)

    0.71%

  • Levered Free Cash Flow (ttm)

    32.94M

Research Analysis: VP4.F

View More

Company Insights: VP4.F

Research Reports: VP4.F

View More